<DOC>
	<DOC>NCT00706355</DOC>
	<brief_summary>PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.</brief_summary>
	<brief_title>A Study of PF-04217903 in Patients With Advanced Cancer</brief_title>
	<detailed_description>The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012. The decision to terminate was not based on any safety concerns.</detailed_description>
	<criteria>Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available Adequate blood cell counts, normal kidney function, and performance status of 0 or 1 Major surgery, radiation therapy or anticancer therapy within 2 weeks of starting study treatment Prior stem cell transplant Active or unstable cardiac disease or heart attack within 12 months of starting study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>